Equity
Equity rose in 2025 from €26,877 to €87,786.
Equity rose in 2025 from €26,877 to €87,786.
The micro format states no turnover.
Green is investment, beige is depreciation.
Short-term debts rose from €5,422 to €39,295.
Eight of the last ten came late. The 2018 accounts came latest: 34 days after the end of the period.
Higher net result than 88% of companies in wholesale trade. Sector median €5,626 · 13,803 companies.
The dashed line is the sector median: 0.4% across 26,888 companies (NACE 46, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro). It does better than 74% of them on solvency, 87% on liquidity, 95% on profitability and 97% on growth.
The bankruptcy probability was computed on 08-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
In July 2024, 34,693 companies had the same profile as AVANOTT has now. Each dot stands for 87 companies, two years later.
That fits the bankruptcy probability of AVANOTT itself: < 0.1% within 12 months.
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 34,693 companies, not a prediction for AVANOTT. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Liquidity is ample, with a current ratio of 3.18 (5.96 in 2024), above the usual 1.5. Short-term debt is 30.9% and cash 85.9% of total assets. 30.9% of the assets are financed with debt and provisions.
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
The company filed its last 7 accounts on average 18 days after the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
| Company | ||||
|---|---|---|---|---|
| AVANOTT Herent | €127,081 | €100,305 | 69.1% | - |
| UVee Tielt-Winge | €140,700 | €64,500 | 30.2% | - |
| GRINTA BENELUX Aarschot | €161,621 | €79,285 | 14.1% | - |
| BO Medical Technologies Belgium Machelen (Brab.) | €125,400 | €168,592 | -47.0% | 2 |
| XV DENTAL Overijse | €102,862 | €84,272 | 6.2% | - |
| Logistik Brussels Woluwe-Saint-Pierre | €142,564 | €70,518 | 37.3% | - |
| C&J Laboratories Belgium Sint-Niklaas | €166,880 | €77,087 | 22.4% | - |
These companies have the same main activity as AVANOTT: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €103,000 and €167,000, founded between 2010 and 2016.
AVANOTT files the micro format. That format states no turnover. The gross margin rose from -€15,766 in 2014 to €100,305 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Turnover ≈ €500,000. Estimated: probably between €240,000 and €920,000.
Higher than 73% of 13,797 companies in 2025.
Higher than 72% of 13,178 companies in 2025.
Higher than 95% of 13,357 companies in 2025.
Net result: top quarter · Equity: middle half · Balance sheet total: middle half · Working capital: middle half
| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet: assets | |||||||||||||
20/58 |
127,081 | 32,299 | 18,419 | 26,651 | 1,994 | 3,919 | 15,745 | 4,802 | 5,372 | 11,710 | 6,406 | 3,637 | |
21/28 |
2,146 | - | - | - | - | - | - | - | - | - | - | - | |
22/27 |
2,146 | - | - | - | - | - | - | - | - | - | - | - | |
23 |
2,146 | - | - | - | - | - | - | - | - | - | - | - | |
29/58 |
124,935 | 32,299 | 18,419 | 26,651 | 1,994 | 3,919 | 15,745 | 4,802 | 5,372 | 11,710 | 6,406 | 3,637 | |
40/41 |
15,808 | 16,026 | 1,638 | 1,176 | 946 | 988 | 635 | 273 | 95 | 4,015 | 4,463 | 826 | |
40 |
11,900 | 12,988 | - | - | - | 666 | - | - | - | 3,761 | - | - | |
41 |
3,908 | 3,038 | 1,638 | 1,176 | 946 | 322 | 635 | 273 | 95 | 254 | 4,463 | 826 | |
54/58 |
109,127 | 16,273 | 16,781 | 25,475 | 1,048 | 2,931 | 15,110 | 4,529 | 5,277 | 7,695 | 1,943 | 2,811 | |
| Balance sheet: equity and liabilities | |||||||||||||
10/49 |
127,081 | 32,299 | 18,419 | 26,651 | 1,994 | 3,919 | 15,745 | 4,802 | 5,372 | 11,710 | 6,406 | 3,637 | |
10/15 |
87,786 | 26,877 | -5,147 | 20,020 | -11,351 | -9,821 | -8,366 | -8,140 | -7,565 | -5,264 | -6,579 | -9,928 | |
10/11 |
6,200 | 6,200 | 6,200 | 6,200 | 6,200 | 6,200 | 6,200 | 6,200 | 6,200 | 6,200 | 6,200 | 6,200 | |
10 |
- | 6,200 | 6,200 | 6,200 | 6,200 | - | - | - | - | - | - | - | |
100 |
- | 19,200 | 19,200 | 19,200 | 19,200 | 19,200 | 19,200 | 19,200 | 19,200 | 19,200 | 19,200 | 19,200 | |
101 |
- | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | |
13 |
81,586 | 20,677 | 13,820 | 13,820 | 66 | 66 | 66 | 66 | 66 | 66 | - | - | |
130/1 |
66 | 66 | 66 | 66 | 66 | 66 | - | - | - | - | - | - | |
130 |
- | 66 | 66 | 66 | 66 | 66 | 66 | 66 | 66 | 66 | - | - | |
1311 |
66 | - | - | - | - | - | - | - | - | - | - | - | |
133 |
81,520 | 20,612 | 13,754 | 13,754 | - | - | - | - | - | - | - | - | |
14 |
- | - | -25,167 | 0 | -17,617 | -16,087 | -14,632 | -14,406 | -13,831 | -11,530 | -12,779 | -16,128 | |
17/49 |
39,295 | 5,422 | 23,566 | 6,631 | 13,345 | 13,740 | 24,111 | 12,942 | 12,937 | 16,974 | 12,985 | 13,565 | |
42/48 |
39,295 | 5,422 | 23,566 | 6,631 | 13,345 | 13,740 | 24,111 | 12,942 | 12,937 | 16,974 | 12,985 | 13,565 | |
42 |
- | - | 22,500 | - | - | - | - | - | - | - | - | - | |
44 |
6,007 | 234 | 342 | 1,021 | 466 | 1,940 | 12,311 | 1,142 | - | 544 | 1,106 | 3,731 | |
440/4 |
6,007 | 234 | 342 | 1,021 | 466 | 1,940 | 12,311 | 1,142 | - | 544 | 1,106 | 3,731 | |
46 |
- | - | - | - | - | - | - | - | - | 4,551 | - | - | |
45 |
30,735 | 4,068 | - | 5,532 | - | - | - | - | 1,058 | - | - | - | |
450/3 |
30,735 | 4,068 | - | 5,532 | - | - | - | - | 1,058 | - | - | - | |
47/48 |
2,553 | 1,120 | 724 | 78 | 12,879 | 11,800 | 11,800 | 11,800 | 11,879 | 11,879 | 11,879 | 9,834 | |
| Income statement | |||||||||||||
9900 |
100,305 | 36,220 | -24,057 | 37,140 | -1,354 | -1,730 | -204 | -267 | -2,276 | 1,388 | 4,983 | -15,766 | |
630 |
486 | - | - | - | - | - | - | - | - | - | - | - | |
640/8 |
- | 63 | - | - | - | - | - | - | - | - | 127 | 362 | |
9901 |
99,819 | 36,158 | -24,057 | 37,140 | -1,354 | -1,730 | -204 | -267 | -2,276 | 1,388 | 4,856 | -16,128 | |
75/76B |
- | - | 1,191 | 24 | - | 900 | - | - | 104 | - | - | - | |
75 |
- | - | 1,191 | 24 | - | 900 | - | - | 104 | - | - | - | |
65/66B |
8,105 | 65 | 1,262 | 261 | 176 | 625 | 22 | 308 | 129 | 73 | 1,507 | - | |
65 |
8,105 | 65 | 1,262 | 261 | 176 | 625 | 22 | 308 | 129 | 73 | 1,507 | - | |
9903 |
91,714 | 36,093 | -24,128 | 36,903 | -1,530 | -1,455 | -226 | -575 | -2,301 | 1,315 | 3,349 | -16,128 | |
67/77 |
30,806 | 4,068 | 1,039 | 5,532 | - | - | - | - | - | - | - | - | |
9904 |
60,908 | 32,025 | -25,167 | 31,371 | -1,530 | -1,455 | -226 | -575 | -2,301 | 1,315 | 3,349 | -16,128 | |
9905 |
60,908 | 32,025 | -25,167 | 31,371 | -1,530 | -1,455 | -226 | -575 | -2,301 | 1,315 | 3,349 | -16,128 | |
| Appropriation of the result | |||||||||||||
9906 |
60,908 | 6,858 | -25,167 | 13,754 | -17,617 | -16,087 | -14,632 | -14,406 | -13,831 | -11,464 | -12,779 | -16,128 | |
14P |
- | -25,167 | - | -17,617 | -16,087 | - | - | - | - | - | - | - | |
691/2 |
60,908 | 6,858 | - | 13,754 | - | - | - | - | - | 66 | - | - | |
6920 |
- | - | - | - | - | - | - | - | - | 66 | - | - | |
6921 |
60,908 | 6,858 | - | 13,754 | - | - | - | - | - | - | - | - | |
| Document | |||||||||||||
The notes to these accounts have 5 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 27-08-2026.
2025 annual accounts filed 27 days after the deadline. Filed on 27 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00433236.
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | micro format | 27-08-2026 | 2026-00433236 | |
| 31-12-2024 | micro format | 29-08-2025 | 2025-00430997 | |
| 31-12-2023 | micro format | 31-07-2024 | 2024-00325685 | |
| 31-12-2022 | micro format | 18-08-2023 | 2023-00339496 | |
| 31-12-2021 | micro format | 30-08-2022 | 2022-20381084 | |
| 31-12-2020 | micro format | 18-08-2021 | 2021-49800224 | |
| 31-12-2019 | micro format | 05-08-2020 | 2020-39400248 | |
| 31-12-2018 | micro format | 03-09-2019 | 2019-61900433 | |
| 31-12-2017 | micro format | 09-08-2018 | 2018-44700156 | |
| 31-12-2016 | micro format | 26-07-2017 | 2017-35800412 | |
| 31-12-2015 | abbreviated format | 29-09-2016 | 2016-62400383 | |
| 31-12-2014 | abbreviated format | 08-06-2015 | 2015-16200571 |
| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100,305 | - | - | - | - | - | - | - | - | - | - | - | ||
| 61,394 | - | - | - | - | - | - | - | - | - | - | - | ||
| 2,631 | - | - | - | - | - | - | - | - | - | - | - | ||
| 92,854 | -508 | -8,694 | 24,427 | -1,883 | -12,179 | 10,581 | -748 | -2,418 | 5,752 | -868 | - | ||
| 85,640 | 26,877 | -5,147 | 20,020 | -11,351 | -9,821 | -8,366 | -8,140 | -7,565 | -5,264 | -6,579 | -9,928 | ||
| 69.1% | 83.2% | -27.9% | 75.1% | - | - | -53.1% | - | -140.8% | -45.0% | -102.7% | - | ||
| 3.18 | 5.96 | 0.78 | 4.02 | - | - | 0.65 | - | 0.42 | 0.69 | 0.49 | - | ||
| 0.45 | 0.20 | - | 0.33 | - | - | - | - | - | - | - | - | ||
| 69.4% | 119.2% | - | 156.7% | - | - | - | - | - | - | - | - | ||
| 47.9% | 99.2% | -136.6% | 117.7% | - | - | -1.4% | - | -42.8% | 11.2% | 52.3% | - | ||
| 12.38 | - | - | - | - | - | - | - | - | - | - | - |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tangible fixed assets | €2,631 | - | - | - | - |
| €486 | - | - | - | - |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
The operating result for 2025 is 176% higher than in 2024 and the highest since 2014. It is the second rise in a row, after the fall in 2023.
Debt's share of the balance-sheet total rises from 16.8% to 30.9%. Equity and debt are higher.
AVANOTT has no parent and no holdings in its annual accounts. XIE Jun is the only director. AVANOTT shares no director with another company.
| PharmaBlock Sciences (Belgium)
registered office since 29-04-2026 |
founded in 2026 1037.459.837 |
| Blomme, Chantal (sole trader)
establishment since 06-07-2004 |
founded in 2004 0866.493.377 |
Deadline for the 2026 accounts: 31-07-2027
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
| Establishment | Since | Unit number |
|---|---|---|
| Schoonzichtlaan 88 registered office 3020 Herent 4618032 Agents specialised in the wholesale of other particular products | 01-01-2014 | 2.228.105.242 |
| Cadastral parcel | Area | Buildings | Height / floors |
|---|---|---|---|
| 24127D0035/00P003 | 1,119 m² | 1 · 158 m² | 7.6 m · 2 |
If something looks wrong or is missing, please tell us.